Oropharyngeal Cancer - Pipeline Review, H1 2020

  • Life Sciences
  • 30 April 2020
  • 550 Pages
  • Formats:    
  • Report Code: 24WT-3587

Oropharyngeal Cancer Pipeline Review H1 - Overview

Oropharyngeal Cancer - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H1 2020, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 3, 21, 10, 1, 1 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
Introduction
Oropharyngeal Cancer - Overview
Oropharyngeal Cancer - Therapeutics Development
Oropharyngeal Cancer - Therapeutics Assessment
Oropharyngeal Cancer - Companies Involved in Therapeutics Development
Oropharyngeal Cancer - Drug Profiles
Oropharyngeal Cancer - Dormant Projects
Oropharyngeal Cancer - Discontinued Products
Oropharyngeal Cancer - Product Development Milestones
Appendix
List of Tables

Number of Products under Development for Oropharyngeal Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Oropharyngeal Cancer - Pipeline by AbbVie Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Admedus Ltd, H1 2020

Oropharyngeal Cancer - Pipeline by Advaxis Inc, H1 2020

Oropharyngeal Cancer - Pipeline by AMI Onco Theranostics LLC, H1 2020

Oropharyngeal Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2020

Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H1 2020

Oropharyngeal Cancer - Pipeline by Biomimetix JV LLC, H1 2020

Oropharyngeal Cancer - Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Oropharyngeal Cancer - Pipeline by Brooklyn ImmunoTherapeutics LLC, H1 2020

Oropharyngeal Cancer - Pipeline by Celldex Therapeutics Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Eisai Co Ltd, H1 2020

Oropharyngeal Cancer - Pipeline by EpicentRx Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Exelixis Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Gilead Sciences Inc, H1 2020

Oropharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2020

Oropharyngeal Cancer - Pipeline by IMV Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Incyte Corp, H1 2020

Oropharyngeal Cancer - Pipeline by Innate Pharma SA, H1 2020

Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2020

Oropharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Oropharyngeal Cancer - Pipeline by Merck & Co Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Merck KGaA, H1 2020

Oropharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020

Oropharyngeal Cancer - Pipeline by PNP Therapeutics Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Precigen Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Shionogi & Co Ltd, H1 2020

Oropharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2020

Oropharyngeal Cancer - Pipeline by Theralase Technologies Inc, H1 2020

Oropharyngeal Cancer - Pipeline by Transgene SA, H1 2020

Oropharyngeal Cancer - Pipeline by Turnstone Biologics Inc, H1 2020

Oropharyngeal Cancer - Pipeline by VasGene Therapeutics Inc, H1 2020

Oropharyngeal Cancer - Dormant Projects, H1 2020

Oropharyngeal Cancer - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Oropharyngeal Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020
CHOOSE YOUR BUYING OPTION

NEED A HELP?

Submit your research need or query below

+91 9169162030 (Asia)
help@primemarketreports.com